Industry & Policy News

[University of Manitoba Today] Three researchers from the Rady Faculty of Health Sciences have been honoured with prestigious grants from Brain Canada’s Future Leaders in Canadian Brain Research program.

[UCLA Health] Dr. Roger Lo at the University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center was awarded a $2 million grant from the National Institutes of Health to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

[Maryland Stem Cell Research Commission (The Daily Record)] The Maryland Stem Cell Research Commission has allocated approximately $4.5 million in new grant awards to advance stem cell research and technology.

[Manufacturer's Monthly] The Australian Government’s Medical Research Future Fund has awarded stem cell research company Magellan Stem Cells $7 million as funding for the company’s Phase III human trial of Magellan’s MAG200.

[Theriva Biologics, Inc] Theriva ™ Biologics, Inc. announced that it has achieved their target patient enrollment in the VIRAGE Phase IIb clinical trial evaluating their lead product candidate VCN-01 plus standard-of-care chemotherapy as a first line therapy for patients with metastatic PDAC.

[Ryvu Therapeutics] Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that the first patient has been dosed in the REMARK study, a Phase II clinical trial investigating RVU120 as a monotherapy for the treatment of patients with LR-MDS.